

## Impact Goals

At the outset of the strategic planning process, CIRM began with a working hypothesis built around four key categories that drive its overarching mission. This initial hypothesis formed the basis for developing a comprehensive set of impact goals.

The result was a set of six final recommended impact goals (framed within the four categories) that will guide our actions and funding priorities. These goals are designed to accelerate the discovery and translation of therapies, advance critical approvals for cell and gene therapies, improve accessibility and affordability, and ensure a diverse and skilled workforce capable of sustaining advancements in regenerative medicine.

### CATEGORY 1—ACCELERATING DISCOVERY & TRANSLATION

- Goal 1—Catalyze the identification and validation of at least 4 novel targets and biomarkers, ensuring integration into preclinical or clinical research for diseases in California.
- Goal 2—Accelerate development and utilization of 5-8 technologies that have the potential to improve safety, efficacy, and/or quality of cell and gene therapies.

### CATEGORY 2—CELL & GENE THERAPY APPROVALS

- Goal 3—Advance 4-7 rare disease projects to BLA.
- Goal 4—Propel 15-20 therapies targeting diseases affecting Californians to late-stage trials.

### CATEGORY 3—ACCESSIBILITY & AFFORDABILITY OF CIRM-FUNDED CELL & GENE THERAPIES

- Goal 5—Ensure that every BLA-ready program has a strategy for access and affordability.

### CATEGORY 4—DIVERSE WORKFORCE DEVELOPMENT

- Goal 6—Bolster CIRM's workforce development programs to address gaps and meet evolving demands in regenerative medicine.

